LETTER TO THE EDITOR Performance of the ViroSeq® HIV-1 Genotyping System v2.0 in Central Africa

Linda Chapdeleine Mekue Mouafo 1, 2, Hélène Péré 2, 3, Angélique Ndjoyi-Mbiguino 4, Donato Koyalta 5, Jean De Dieu Longo 6, François-Xavier Mbopi-Kéou 7, Coumba Toure Kane 8, Laurent Bélec*, 2, 3
1 University of Dschang, Dschang, Cameroon
2 Assistance Publique - Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Paris, France
3 Faculté de Médecine Paris Descartes, Université Paris Descartes (Paris V), Sorbonne Paris Cité, Paris, France
4 Université des Sciences de la Santé, Libreville, Gabon
5 Ministère de la Santé Publique, N’Djamena, Chad
6 Centre National de Référence des Maladies Sexuellement Transmissibles, et de la Thérapie Antirétrovirale, and Unité de Recherches et d’Intervention sur les Maladies Sexuellement Transmissibles et le SIDA, Département de Santé Publique, Faculté des Sciences de la Santé de Bangui, Bangui, Central African Republic
7 Laboratoire National de Santé Hygiène Mobile, Ministry of Public Health, and Université de Yaoundé I, Yaoundé, Cameroon
8 Laboratoire de Bactériologie-virologie, CHU Aristide Le Dantec, Dakar, Senegal

Article Metrics

CrossRef Citations:
Total Statistics:

Full-Text HTML Views: 2292
Abstract HTML Views: 1454
PDF Downloads: 298
Total Views/Downloads: 4044
Unique Statistics:

Full-Text HTML Views: 877
Abstract HTML Views: 734
PDF Downloads: 213
Total Views/Downloads: 1824

© Mouafo et al.; Licensee Bentham Open.

open-access license: This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.

* Address correspondence to this author at the Hôpital Européen Georges Pompidou, Laboratoire de Virologie, 20 Rue Leblanc 75015 Paris, France; Tel: (33)1 56 09 39 59; Fax: (33)1 56 09 24 47; E-mail:


Resistance genotypes in pol gene of HIV-1 were obtained by the ViroSeq® HIV-1 Genotyping System v2.0 (Celera Diagnostics, Alameda, CA, USA) in 138 of 145 (95%) antiretroviral treatment-experienced adults in virological failure living in Central Africa (Cameroon, Central African Republic, Chad, Gabon). HIV-1 group M exhibited broad genetic diversity. Performance of the 7 ViroSeq® sequencing primers showed high failure rate, from 3% to 76% (D: 76%; F: 17%; A and H: 15%; G and B: 4%; C: 3%). These findings emphasize the need of updating the ViroSeq® HIV-1 genotyping system for non-B subtypes HIV-1.

Keywords: Central Africa, non-B subtypes HIV-1, VirosSeq®HIV-1 Genotyping System v2.0.